Safinamide Mesylate API

Name	Safinamide Mesylate
Chinese name	甲磺酸沙芬酰胺
Cas Number	202825-46-5
Source	India
Qualifications	USDMF/-/-/-/-

On March 22, 2017, the FDA approved the monoamine oxidase B inhibitor Safinamide of Zambon and Newron in Italy. This is also the first new chemical entity approved for the treatment of Parkinson’s disease (NCE) in the United States in more than 10 years. ), used to extend the efficacy of levodopa. Safinamide is a third-generation MAO-B inhibitor that can reduce the degradation of secreted dopamine and help maintain the concentration of dopamine in the brain. In addition, safinamide can also block voltage-dependent sodium channels on neurons, thereby inhibiting the release of glutamate. Therefore, safinamide has become a novel treatment for Parkinson's disease with both dopaminergic and non-dopaminergic mechanisms. Compared with the first and second-generation MAO-B inhibitors, safinamide has higher selectivity for MAO-B, and its inhibitory effect on monoamine oxidase is reversible. The physiological activity of MAO-B can be completely after 8 hours of stopping the drug. restore. Compared with the old MAO-B inhibitors such as selegiline and rasagiline, safinamide is a new drug for the treatment of Parkinson's disease with high selectivity, good biological safety and obvious therapeutic effect. From 2015 to 2017, the parkinson's disease treatment drug market in public hospitals in China's key cities was 265 million yuan, 298 million yuan and 354 million yuan, with an average annual growth rate of 13.95%. It is predicted that the global Parkinson’s disease market will reach US$3.2 billion in 2021, driven by the launch of new drugs.

Hot Tags: safinamide mesylate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Pregabalin API, Idebenone API, Vinpocetine API, Dapoxetine API, Gabapentin API, Bemeprost API

• Previous: Selenium Disulfide API
• Next: Zinc Gluconate API